Free shipping on all orders over $ 500

RO5126766 (VS-6766)

Cat. No. M10369

All AbMole products are for research use only, cannot be used for human consumption.

RO5126766 (VS-6766) Structure
Synonym:

CH5126766; VS 6766; Avutometinib

Size Price Availability Quantity
1mg USD 75  USD75 In stock
5mg USD 160  USD160 In stock
10mg USD 250  USD250 In stock
25mg USD 460  USD460 In stock
50mg USD 760  USD760 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

RO5126766 (CH5126766, VS 6766) is a first-in-class dual MEK/RAF inhibitor with IC50 values of 8.2 nM, 19 nM, 56 nM and 160 nM for BRAF V600E, BRAF, CRAF and MEK1, respectively. In HCT116 KRAS-mutant colorectal cancer cells, CH5126766 significantly reduces the levels of phospho-MEK and phospho-ERK. CH5126766 inhibits RAF kinase by binding to MEK1, and causes MEK to become a dominant negative inhibitor of RAF. In Raf or RAS-mutant cell lines SK-MEL-28, SK-MEL-2, MIAPaCa-2, SW480, HCT116, and PC3 cells, CH5126766 inhibits cell growth with IC50 of 65, 28, 40, 46, and 277 nM, respectively.

In vivo, RO5126766 (25 mg/kg, p.o.) inhibits ERK signaling output more effectively in an HCT116 (G13D KRAS) mouse xenograft model than a standard MEK inhibitor that induces MEK phosphorylation, and has potent antitumor activity. In the HCT116 (K-ras) and COLO205 (B-raf) mutant xenografts, CH5126766 (0.3 mg/kg) causes significant decreases in [18F]FDG uptake.

Chemical Information
Molecular Weight 471.46
Formula C21H18FN5O5S
CAS Number 946128-88-7
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Mahiro Iizuka-Ohashi, et al. Oncotarget. Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells

[2] Makoto Wada, et al. PLoS One. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells

[3] Tetyana Tegnebratt, et al. EJNMMI Res. [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

[4] Nobuya Ishii, et al. Cancer Res. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity

[5] Maria Martinez-Garcia, et al. Clin Cancer Res. phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors

Related MEK Products
Balamapimod

Balamapimod (MKI 833) is a reversible Ras/Raf/MEK inhibitor with potential anti-tumor activity.

PD-334581 

PD-334581 is a MEK1 inhibitor.

Tunlametinib

Tunlametinib, an antineoplastic agent, is a MEK1/2 inhibitor.

Glycinexylidide

Glycinexylidide (GX) is the active metabolite of Lidocaine.

Xantocillin

Xantocillin (Xanthocillin X) is a marine agent extracted from Penicillium commune, induces autophagy through inhibition of the MEK/ERK pathway.

  Catalog
Abmole Inhibitor Catalog




Keywords: RO5126766 (VS-6766), CH5126766; VS 6766; Avutometinib supplier, MEK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.